Agenus' QS-21 Stimulon(R) Adjuvant Selected for Biodefense Program
June 14, 2011 07:00 ET
|
Agenus Inc.
LEXINGTON, Mass., June 14, 2011 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN) announced today a license agreement with Integrated BioTherapeutics Inc. (IBT) for the use of the QS-21 Stimulon®...
New Data From Phase 2 Brain Cancer Study With Prophage Series G-200 (HSPPC-96) Shows Improved Overall Survival
June 06, 2011 09:00 ET
|
Agenus Inc.
LEXINGTON, Mass., June 6, 2011 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN), a leading developer of therapeutic vaccines for cancer and infectious diseases, today announced results from a Phase 2...
Agenus to Webcast 2011 Annual Shareholders Meeting
June 01, 2011 07:00 ET
|
Agenus Inc.
LEXINGTON, Mass., June 1, 2011 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN) invites investors and the general public to its 2011 Annual Shareholders Meeting at 5:00 p.m. ET on Wednesday, June 15. The...
Agenus Announces Investor Briefing at the American Society of Clinical Oncology (ASCO) 2011 Chicago Meeting
May 24, 2011 12:00 ET
|
Agenus Inc.
LEXINGTON, Mass., May 24, 2011 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN) today announced that it will host an investor/analyst briefing on June 6th from 2-3 p.m. CT (3-4 p.m. ET). The purpose of...
New Data From Prophage G-200 Phase 2 Recurrent Glioma Trial to be Presented at the American Society of Clinical Oncology (ASCO) 2011 Annual Meeting
May 18, 2011 18:00 ET
|
Agenus Inc.
LEXINGTON, Mass., May 18, 2011 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN) today announced that new data from a Phase 2 trial testing the Prophage G-200 vaccine (HSPPC-96; vitespen) in recurrent...
Agenus Reports First Quarter 2011 Financial Results
April 28, 2011 07:00 ET
|
Agenus Inc.
LEXINGTON, Mass., April 28, 2011 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN) reported today its results for the first quarter of 2011. The company reported a net loss attributable to common...
Agenus to Report First Quarter Financial Results on April 28, 2011; Conference Call to Follow
April 21, 2011 07:00 ET
|
Agenus Inc.
LEXINGTON, Mass., April 21, 2011 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN) will release its first quarter financial results before the market opens on April 28, 2011.
Agenus executives will host...
Data From Prophage Phase 2 Glioma Trial to be Presented at the American Society of Clinical Oncology (ASCO) 2011 Annual Meeting
April 06, 2011 07:00 ET
|
Agenus Inc.
LEXINGTON, Mass., April 6, 2011 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN) announced today that new data from a Phase 2 trial testing the Prophage G-200 vaccine (HSPPC-96; vitespen) in recurrent...
Agenus Receives NASDAQ Delisting Notification
March 04, 2011 09:00 ET
|
Agenus Inc.
LEXINGTON, Mass., March 4, 2011 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN) announced today that the company received a letter from the Listing Qualifications Staff of The NASDAQ Stock Market LLC...
Agenus to Present at the 31st Annual Cowen and Company Health Care Conference
March 02, 2011 11:45 ET
|
Agenus Inc.
Agenus Inc. (Nasdaq:AGEN) announced today that Agenus management will present a corporate overview at the 31st Annual Cowen and Company Health Care Conference on Wednesday, March 9th at 8:45 am ET...